Strides, TLC partner to launch black fungus drug in India PTI
Updated May 27, 2021, 3:13 pm IST
AmphoTLC will be imported from Taiwan by Stelis Biopharma Pvt Ltd
The Central Drugs Standard Control Organization (CDSCO) has approved TLC s new drug application. (Photo: PTI)
New Delhi: Strides Pharma Science and Taiwan-based specialty pharmaceutical firm TLC have partnered to launch Liposomal Amphotericin B, a drug used in the treatment of mucormycosis (black fungus), in India.
The Central Drugs Standard Control Organization (CDSCO) has approved TLC s new drug application (NDA) of Amphotericin B Liposome for Injection 50mg in India for immediate importation per approved usage and indication, Strides and TLC said in a joint statement on Thursday.
Top headlines: Covishield at Rs 400; Covid shaves off a 5th of ONGC capex business-standard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from business-standard.com Daily Mail and Mail on Sunday newspapers.
The chief executive officer of Stelis Biopharma Pvt Ltd. stepped down from the Indian pharmaceutical firm barely a year after taking the helm, and days after the company announced a deal to manufacturer at least 200 million doses of Russia’s coronavirus vaccine. Roger Lias, who accepted the CEO job at unlisted Stelis in late 2019 when the pandemic was in its early stages, left on March 31, according to an automated out-of-office email Bloomberg News received from his account. “I continue to support the company,” he said, according to the email. Stelis and its majority owner Strides Pharma Science Ltd. both headquartered in the southern Indian city of Bengaluru have yet to publicly announce his departure, but Lias’ profile is now absent from the Stelis website.
Stelis CEO Steps Down After Indian Firm Inks Russia Vaccine Deal
Apr 21 2021, 5:42 PM
April 21 2021, 12:48 PM
April 21 2021, 5:42 PM
(Bloomberg) The chief executive officer of Stelis Biopharma Pvt Ltd. stepped down from the Indian pharmaceutical firm barely a year after taking the helm, and days after the company announced a deal to manufacturer at least 200 million doses of Russiaâs coronavirus vaccine.
(Bloomberg) The chief executive officer of Stelis Biopharma Pvt Ltd. stepped down from the Indian pharmaceutical firm barely a year after taking the helm, and days after the company announced a deal to manufacturer at least 200 million doses of Russiaâs coronavirus vaccine.
Citizen groups and businesses are coming forward to fight India s Covid-19 vaccine hesitancy scroll.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from scroll.in Daily Mail and Mail on Sunday newspapers.